Novel approach to addressing pigment loss disorder affecting an estimated 45 million individuals worldwide...
World-first stroke study CUV801 evaluating afamelanotide...
LONDON, April 29, 2022 (GLOBE NEWSWIRE) -- Â Â Â Dear shareholders, friends, Both from a professional viewpoint and as largest private holder, I have...
Melanocortin drug NEURACTHEL® (ACTH) added for neurological, endocrinological and degenerative disorders...
SCENESSE ® (afamelanotide 16mg) to be evaluated in xeroderma pigmentosum variant (XP-V)
MELBOURNE, Australia, Oct. 28, 2020 (GLOBE NEWSWIRE) -- The drug afamelanotide will be used for the first time in patients with acute stroke. The study will evaluate the safety and efficacy of afamelanotide,...
MELBOURNE, Australia, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Xeroderma pigmentosum (XP) patient receives SCENESSE ® treatment
Drug tested to protect skin and regenerate DNA, firstly in XP patients at 10,000-fold skin cancer risk
Bespoke Research & Development Centre to advance innovative pharmaceutical and OTC products
Drug to be evaluated in patients with acute and systemic diseases